Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to Agalsidase Beta in Classic Fabry Disease
NCT04143958Phase 4Withdrawn
- Sponsor
- Sanofi
- Start
- Sep 2020
- Primary completion
- Nov 2023
- Modality
- Replacement Enzymes
01
Overview
A Phase 4 trial of agalsidase beta in Fabry disease (FD), sponsored by Sanofi. Planned start Sep 2020; status: withdrawn.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT04143958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04143958.